Search Results - "Backert, Linus"

Immunoinformatics and epitope prediction in the age of genomic medicine.

Authors: Backert, Linus Kohlbacher, Oliver

Source: Genome Medicine. 11/20/2015, Vol. 7, p1-12. 12p.

ToxDBScan: Large-Scale Similarity Screening of Toxicological Databases for Drug Candidates.

Authors: Römer, Michael Backert, Linus Eichner, Johannes et al.

Source: International Journal of Molecular Sciences. Oct2014, Vol. 15 Issue 10, p19037-19055. 19p. 1 Color Photograph, 1 Diagram, 4 Charts, 1 Graph.

This result is not displayed to guests.
Login for full access.

Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: an open-label, non-randomised, prospective, first-in-human phase 1 clinical trial.

Authors: Alberer, Martin Gnad-Vogt, Ulrike Henoch Sangjoon Hong et al.

Source: Lancet. 9/23/2017, Vol. 390 Issue 10101, p1511-1520. 10p. 1 Diagram, 3 Charts, 2 Graphs.

Subjects: Messenger RNA, Rabies vaccines, Antigens, Glycoproteins, Intramuscular injections, Rabies prevention, Clinical trials, Comparative studies, Drug administration, Drug side effects, Immunoglobulins, Longitudinal method, Research methodology, Medical cooperation, Research, RNA, Viral antibodies, Evaluation research, Blind experiment

Geographic Terms: Germany

This result is not displayed to guests.
Login for full access.

HLA ligandome analysis of primary chronic lymphocytic leukemia (CLL) cells under lenalidomide treatment confirms the suitability of lenalidomide for combination with T-cell-based immunotherapy.

Authors: Nelde, Annika Kowalewski, Daniel J. Backert, Linus et al.

Source: OncoImmunology. Apr2018, Vol. 7 Issue 4, p1-12. 12p.

Integrative -omics and HLA-ligandomics analysis to identify novel drug targets for ccRCC immunotherapy.

Authors: Reustle, Anna Di Marco, Moreno Meyerhoff, Carolin et al.

Source: Genome Medicine. 3/30/2020, Vol. 12 Issue 1, p1-24. 24p.

Favorable immune signature in CLL patients, defined by antigen-specific T-cell responses, might prevent second skin cancers.

Authors: Walz, Juliane Sarah Kanz, Lothar Nelde, Annika et al.

Source: Leukemia & Lymphoma. Aug2018, Vol. 59 Issue 8, p1949-1958. 10p.

Characterization of the Canine MHC Class I DLA-88*50101 Peptide Binding Motif as a Prerequisite for Canine T Cell Immunotherapy.

Authors: Barth, Sharon M. Schreitmüller, Christian M. Proehl, Franziska et al.

Source: PLoS ONE. 11/28/2016, Vol. 11 Issue 11, p1-19. 19p.

AureoWiki ̵ The repository of the Staphylococcus aureus research and annotation community.

Authors: Fuchs, Stephan Mehlan, Henry Bernhardt, Jörg et al.

Source: International Journal of Medical Microbiology. Aug2018, Vol. 308 Issue 6, p558-568. 11p.

The natural HLA ligandome of glioblastoma stem-like cells: antigen discovery for T cell-based immunotherapy.

Authors: Neidert, Marian Christoph Kowalewski, Daniel Johannes Silginer, Manuela et al.

Source: Acta Neuropathologica. Jun2018, Vol. 135 Issue 6, p923-938. 16p.

Haploidentical hematopoietic cell transplantation using in vitro T cell depleted grafts as salvage therapy in patients with disease relapse after prior allogeneic transplantation.

Authors: Haen, Sebastian Groh, Christiane Schumm, Michael et al.

Source: Annals of Hematology. May2017, Vol. 96 Issue 5, p817-827. 11p.

The antigenic landscape of multiple myeloma: mass spectrometry (re)defines targets for T-cell–based immunotherapy.

Authors: Walz, Simon Stickel, Juliane S. Kowalewski, Daniel Johannes et al.

Source: Blood. 9/3/2015, Vol. 126 Issue 10, p1203-1213. 11p.

Distinct transcriptional changes in non-small cell lung cancer patients associated with multi-antigenic RNActive® CV9201 immunotherapy.

Authors: Hong, Henoch S. Koch, Sven D. Scheel, Birgit et al.

Source: OncoImmunology. 2016, Vol. 5 Issue 12, p1-1. 1p.

HLA Ligand Atlas DIA: extending the benign immunopeptidomics resource with increased sensitivity through data-independent acquisition mass spectrometry.

Authors: Bichmann L Marcu A Kowalewski DJ et al.

Source: Journal for immunotherapy of cancer [J Immunother Cancer] 2025 Aug 31; Vol. 13 (8). Date of Electronic Publication: 2025 Aug 31.

Publication Type: Journal Article

Journal Info: Publisher: BMJ Publishing Group Ltd Country of Publication: England NLM ID: 101620585 Publication Model: Electronic Cited Medium: Internet ISSN: 2051-1426 (Electronic) Linking ISSN: 20511426 NLM ISO Abbreviation: J Immunother Cancer Subsets: MEDLINE

Author Correction: Autologous T cell therapy for PRAME⁺ advanced solid tumors in HLA-A*02⁺ patients: a phase 1 trial.

Authors: Wermke M Araujo DM Chatterjee M et al.

Source: Nature medicine [Nat Med] 2025 Jul; Vol. 31 (7), pp. 2453.

Publication Type: Published Erratum

Journal Info: Publisher: Nature Publishing Company Country of Publication: United States NLM ID: 9502015 Publication Model: Print Cited Medium: Internet ISSN: 1546-170X (Electronic) Linking ISSN: 10788956 NLM ISO Abbreviation: Nat Med Subsets: MEDLINE; PubMed not MEDLINE

Autologous T cell therapy for PRAME⁺ advanced solid tumors in HLA-A*02⁺ patients: a phase 1 trial.

Authors: Wermke M Araujo DM Chatterjee M et al.

Source: Nature medicine [Nat Med] 2025 Jul; Vol. 31 (7), pp. 2365-2374. Date of Electronic Publication: 2025 Apr 09.

Publication Type: Journal Article; Clinical Trial, Phase I; Multicenter Study

Journal Info: Publisher: Nature Publishing Company Country of Publication: United States NLM ID: 9502015 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1546-170X (Electronic) Linking ISSN: 10788956 NLM ISO Abbreviation: Nat Med Subsets: MEDLINE

First-in-human dose escalation trial to evaluate the clinical safety and efficacy of an anti-MAGEA1 autologous TCR-transgenic T cell therapy in relapsed and refractory solid tumors.

Authors: Wermke M Holderried TAW Luke JJ et al.

Source: Journal for immunotherapy of cancer [J Immunother Cancer] 2024 Jul 22; Vol. 12 (7). Date of Electronic Publication: 2024 Jul 22.

Publication Type: Journal Article; Clinical Trial, Phase I

Journal Info: Publisher: BMJ Publishing Group Ltd Country of Publication: England NLM ID: 101620585 Publication Model: Electronic Cited Medium: Internet ISSN: 2051-1426 (Electronic) Linking ISSN: 20511426 NLM ISO Abbreviation: J Immunother Cancer Subsets: MEDLINE

Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-in-Human Clinical Trial in Patients with Advanced Metastatic Cancer.

Authors: Tsimberidou AM Guenther K Andersson BS et al.

Source: Cancer immunology research [Cancer Immunol Res] 2023 Jul 05; Vol. 11 (7), pp. 925-945.

Publication Type: Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

Journal Info: Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 101614637 Publication Model: Print Cited Medium: Internet ISSN: 2326-6074 (Electronic) Linking ISSN: 23266066 NLM ISO Abbreviation: Cancer Immunol Res Subsets: MEDLINE

HLA Ligand Atlas: a benign reference of HLA-presented peptides to improve T-cell-based cancer immunotherapy.

Authors: Marcu A Bichmann L Kuchenbecker L et al.

Source: Journal for immunotherapy of cancer [J Immunother Cancer] 2021 Apr; Vol. 9 (4).

Publication Type: Journal Article; Research Support, Non-U.S. Gov't

Journal Info: Publisher: BMJ Publishing Group Ltd Country of Publication: England NLM ID: 101620585 Publication Model: Print Cited Medium: Internet ISSN: 2051-1426 (Electronic) Linking ISSN: 20511426 NLM ISO Abbreviation: J Immunother Cancer Subsets: MEDLINE